S.-W. Kim

机构：Ulsan College, Asan Medical Center, University of Ulsan

发表论文 24 篇 · 总被引 172 次 · h-index 6

代表论文

• Belotecan, new camptothecin analogue, is active in patients with small-cell lung cancer: results of a multicenter early phase II study (2007 · Annals of Oncology · 被引 60)
• Nivolumab (NIVO) + low-dose ipilimumab (IPI) vs platinum-doublet chemotherapy (chemo) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): CheckMate 227 part 1 final analysis (2019 · Annals of Oncology · 被引 33)
• First-line nivolumab + ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patients (2022 · ESMO Open · 被引 25)
• Primary results of ALESIA: A randomised, phase III, open-label study of alectinib vs crizotinib in Asian patients with treatment-naïve ALK+ advanced NSCLC (2018 · Annals of Oncology · 被引 12)
• PL03.13 Osimertinib With/Without Platinum-Based Chemotherapy as First-line Treatment in Patients with EGFRm Advanced NSCLC (FLAURA2) (2023 · Journal of Thoracic Oncology · 被引 10)
• Primary results of ALESIA: Phase III, randomised open-label study of alectinib (ALC) vs crizotinib (CRZ) in Asian patients (pts) with treatment-naïve ALK+ advanced non-small-cell lung cancer (NSCLC) (2018 · Annals of Oncology · 被引 6)